Информация предназначена только для профессионалов в области здравоохранения.
Вы можете зайти как пользователь социальных сетей
Университет им. Давида Бен-Гуриона в Негеве. 8410501, Израиль, Беэр-Шева 2 ГБОУ ВПО «Ставропольский государственный медицинский университет» Минздрава России. 355017, Россия, Ставрополь, ул. Мира, д. 310 3 ФГБО УВО РНИМУ им. Н.И. Пирогова, Москва, Россия
Список исп. литературыСкрыть список 1. Морозов ПВ, Беккер РА, Быков ЮВ. О возможной роли некоторых психотропных препаратов в терапии COVID-19 (Краткий обзор) //Экспериментальная и клиническая фармакология. – 2021. – Т. 84. – №. 2. – С. 104-112. 2. Петрова НН, Морозов ПВ, Маркин АВ, Беккер РА, Быков ЮВ. Пандемия COVID-19: актуальные вызовы времени, а также новейшие данные к вопросу рационального выбора психофармакотерапии у пациентов с SARS-CoV-2 //Психиатрия и психофармакотерапия. – 2020. – Т. 22. – №. 6. – С. 8-24. 3. Инструкция по медицинскому применению лекарственного препарата Сероквель® (РУ N013468/01 от 21.11.2008 (с изм. от 07.12.2020). 4. Anmella G, Arbelo N, Fico G et al. COVID-19 in patients with psychiatric disorders: Real-world clinical recommendations from an expert team in consultation-liaison psychiatry. J Affect Disord. 2020;274:1062-1067. 5. Arango C, Bernardo M. The effect of quetiapine on aggression and hostility in patients with schizophrenia. Hum Psychopharmol. 2005;20(4):237–241. 6. Beach SR, Praschan NC, Hogan C et al. Delirium in COVID-19: A case series and exploration of potential mechanisms for central nervous system involvement. Gen Hosp Psychiatry. 2020;65:47-53. 7. Bi X, Yan B, Fang S et al. Quetiapine regulates neurogenesis in ischemic mice by inhibiting NF-kappaB p65/p50 expression. Neurol Res. 2009;31:159–166. 8. Bian Q, Kato T, Monji A et al. The effect of atypical antipsychotics, perospirone, ziprasidone and quetiapine on microglial activation induced by interferon-gamma. Prog Neuropsychopharmacol Biol Psychiatry. 2008; 32:42–48. 9. Cantillon M, Goldstein JM. Quetiapine fumarate reduces aggression and hostility in patients with schizophrenia; Poster presented at: American Psychiatric Association 151st Annual Meeting; May 30–June 4, 1998; Toronto, Canada. 10. Carrajo García CA, Alonso Sánchez EB, Hernández Huerta D, Gómez-Arnau J. Covid-19 treatment-induced neuropsychiatric adverse effects. Gen Hosp Psychiatry. 2020;67:163-164. 11. Chatterjee SS, Malathesh BC, Das S, Singh OP. Interactions of recommended COVID-19 drugs with commonly used psychotropics. Asian J Psychiatr. 2020;52:102173. 12. Chengappa KN, Goldstein JM, Greenwood M et al. A post hoc analysis of the impact on hostility and agitation of quetiapine and haloperidol among patients with schizophrenia. Clin Ther. 2003;25(2):530–541. 13. Cross AJ, Widzowski D, Maciag C et al. Quetiapine and its metabolite norquetiapine: translation from in vitro pharmacology to in vivo efficacy in rodent models. Br J Pharmacol. 2016;173(1):155-66. 14. Dinesh AA, Islam J, Khan J et al. Effects of antipsychotic drugs: cross talk between the nervous and innate immune system. CNS Drugs. 2020;34:1229. 15. Ely EW, Shintani A, Truman B et al. Delirium as a predictor of mortality in mechanically ventilated patients in the intensive care unit. JAMA. 2004;291(14):1753–1762. 16. Girgis RR, Lieberman JA. Anti-viral properties of antipsychotic medications in the time of COVID-19. Psychiatry Res. 2021;295:113626. 17. Gobbi G, Comai S, Debonnel G. Effects of quetiapine and olanzapine in patients with psychosis and violent behavior: a pilot randomized, open-label, comparative study. Neuropsychiatr Dis Treat. 2014;10:757-65. 18. Helms J, Kremer S, Merdji H et al. Neurologic Features in Severe SARS-CoV-2 Infection. N Engl J Med. 2020;382(23):2268-2270. 19. Hill L, Lee K C. Pharmacotherapy considerations in patients with HIV and psychiatric disorders: Focus on anti-depressants and antipsychotics. Annals of Pharmacotherapy. 2013;47(1):75–89. 20. Ignácio ZM, Da Silva RS, Plissari ME et al. Physical exercise and Neuroinflammation in major depressive disorder. Mol Neurobiol. 2019;56:8323–8335. 21. Jin B, Liu H. Comparative efficacy and safety of therapy for the behavioral and psychological symptoms of dementia: a systemic review and Bayesian network meta-analysis. J Neurol. 2019;266(10):2363–2375. 22. Kalali A, Schulz SC, Kahn RS et al. Effectiveness of once-daily extended release quetiapine fumarate (quetiapine xr) for excitability, hostility and aggression in schizophrenia. Schizophr Res. 2008;98(Suppl 1):164. 23. Kato T, Monji A, Hashioka S, Kanba S. Risperidone significantly inhibits interferon-gamma-induced microglial activation in vitro . Schizophr. Res. 2007;92 (1–3):108–115. 24. Kim H, Bang J, Chang HW et al. Anti-inflammatory effect of quetiapine on collagen-induced arthritis of mouse. Eur J Pharmacol. 2012;678(1-3):55-60. 25. Kotfis K, Marra A, Ely EW. ICU delirium–a diagnostic and therapeutic challenge in the intensive care unit. Anaesthesiol Intensive Ther. 2018;50(2):160–167. 26. Kotfis K, Williams Roberson S, Wilson J, et al. COVID-19: what do we need to know about ICU delirium during the SARS-CoV-2 pandemic? Anaesthesiol Intensive Ther. Epub ahead of print 18 May 2020. 27. Lee SW, Yang JM, Moon SY et al. Association between mental illness and COVID-19 susceptibility and clinical outcomes in South Korea: a nationwide cohort study. Lancet Psychiatry. 2020;7(12):1025–1031. 28. Li YC, Bai WZ, Hashikawa T. The neuroinvasive potential of SARS-CoV2 may play a role in the respiratory failure of COVID-19 patients. J Med Virol 2020; 92: 552–555. 29. Lu J, Hou Y, Ge S et al. Screened antipsychotic drugs inhibit SARS-CoV-2 binding with ACE2 in vitro. Life Sci. 2021;266:118889/ 30. Maan JS, Ershadi M, Khan I, Saadabadi A. Quetiapine. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2021 Jan.2020 Sep 25. Bookshelf ID: NBK459145 31. Mao L, Jin H, Wang M, Hu Y et al. Neurologic manifestations of hospitalized patients with coronavirus disease 2019 in Wuhan, China. JAMA Neurol. 2020;77(6):683-690. 32. Mei F, Guo S, He Y et al. Quetiapine, an atypical antipsychotic, is protective against autoimmune-mediated demyelination by inhibiting effector T cell proliferation. 2012; PLoS One 7:e42746. 33. Mohamadian M, Chiti H, Shoghli A et al. COVID-19: Virology, biology and novel laboratory diagnosis. J Gene Med. 2021;23(2):e3303. 34. Mohebbi N, Talebi A, Moghadamnia M et al. Drug Interactions of Psychiatric and COVID-19 Medications. Basic Clin Neurosci. 2020;11(2):185-200. 35. Moreno C, Wykes T, Galderisi S et al. How mental health care should change as a consequence of the COVID-19 pandemic. Lancet Psychiatry. 2020;7(9):813-824. 36. Nagata T, Nakajima S, Shinagawa S et al. Baseline Predictors of Antipsychotic Treatment Continuation and Response at Week 8 in Patients with Alzheimer's Disease with Psychosis or Aggressive Symptoms: An Analysis of the CATIE-AD Study. J Alzheimers Dis. 2017;60(1):263-272. 37. Nasrallah HA, Tandon R. Efficacy, Safety, and Tolerability of Quetiapine in Patients With Schizophrenia. J Clin Psychiatry. 2002;63(Suppl 13):12–20. 38. National Institute for Health and Care Excellence (NICE) in collaboration with NHS England and NHS Improvement Managing COVID-19 symptoms (including at the end of life) in the community: summary of NICE guidelines. BMJ (Clinical Research Ed) 2020;369:m1461. 39. O’Hanlon S, Inouye SK. Delirium: a missing piece in the COVID-19 pandemic puzzle. Age Ageing. 2020;49(4):497-498. 40. Obuchowicz E, Bielecka-Wajdman AM, Paul-Samojedny M, Nowacka M. Different influence of antipsychotics on the balance between pro- and anti-inflammatory cytokines depends on glia activation: an in vitro study. Cytokine. 2017;94:37–44. 41. Ostuzzi G, Gastaldon C, Papola D et al. Pharmacological treatment of hyperactive delirium in people with COVID-19: rethinking conventional approaches. Ther Adv Psychopharmacol. 2020;10:2045125320942703. 42. Plasencia-García BO, Rodríguez-Menéndez G, Rico-Rangel MI et al. Drug-drug interactions between COVID-19 treatments and antipsychotics drugs: integrated evidence from 4 databases and a systematic review. Psychopharmacology (Berl). 2021;238(2):329-340. 43. Plaze M, Attali D, Petit AC et al. Repurposing of chlorpromazine in COVID-19 treatment: the reCoVery study. Encephale. 2020;46:S35–s39. 44. Pollack TM, McCoy C, Stead W. Clinically significant adverse events from a drug interaction between quetiapine and atazanavir-ritonavir in two patients. Pharmacotherapy. 2009;29(11):1386–91. 45. Rogers JP, Chesney E, Oliver D et al. Psychiatric and neuropsychiatric presentations associated with severe coronavirus infections: a systematic review and meta-analysis with comparison to the COVID-19 pandemic. Lancet Psychiatry. 2020;7(7):611-627. 46. Saller CF, Salama AI. Seroquel: biochemical profile of a potential atypical antipsychotic. Psychopharmacology (Berl). 1993;112(2-3):285-92. 47. Seminog OO, Goldacre MJ. Risk of pneumonia and pneumococcal disease in people with severe mental illness: English record linkage studies. Thorax. 2013;68:171–176. 48. Stahl SM. Stahl’s Essential Psychopharmacology: Neuroscientific Basis and Practical Applications. Cambridge university press, 2013. 626 p. ISBN 978-1107686465. 49. Suttajit S, Srisurapanont M, Maneeton N, Maneeton B. Quetiapine for acute bipolar depression: a systematic review and meta-analysis. Drug Des Devel Ther. 2014;8:827-38. 50. Varatharaj A, Thomas N, Ellul MA et al. Neurological and neuropsychiatric complications of COVID-19 in 153 patients: a UK-wide surveillance study. Lancet Psychiatry. 2020;7(10):875-882. 51. Vasilevskis EE, Chandrasekhar R, Holtze CH et al. The cost of ICU delirium and coma in the intensive care unit patient. Med Care. 2018;56(10):890–897. 52. Villarreal G, Hamner MB, Cañive JM et al. Efficacy of Quetiapine Monotherapy in Posttraumatic Stress Disorder: A Randomized, Placebo-Controlled Trial. Am J Psychiatry. 2016;173(12):1205-1212. 53. Wan R, McKenzie CA, Taylor D, et al. Acute kidney injury as a risk factor of hyperactive delirium: a case control study. J Crit Care 2020; 55: 194–197. 54. Wang Q, Xu R, Volkow ND. Increased risk of COVID‐19 infection and mortality in people with mental disorders: analysis from electronic health records in the United States. World Psychiatry. 2021;20(1):124–130. 55. Yan C, Luo Z, Li W et al. Disturbed Yin-Yang balance: stress increases the susceptibility to primary and recurrent infections of herpes simplex virus type 1. Acta Pharm Sin B. 2020;10:383–398. 56. Yao H, Chen JH, Xu YF. Patients with mental health disorders in the COVID-19 epidemic. Lancet Psychiatry. 2020;7:e21 57. Yeo QM, Wiley TL, Smith MN, Hammond DA. Oral Agents for the Management of Agitation and Agitated Delirium in Critically Ill Patients. Crit Care Nurs Q. 2017;40(4):344–362. doi: 10.1097/CNQ.0000000000000172. 58. Zhu S, Shi R, Li V et al. Quetiapine attenuates glial activation and proinflammatory cytokines in APP/PS1 transgenic mice via inhibition of nuclear factor-κB pathway. Int J Neuropsychopharmacol. 2014;18(3):pyu022.